Tepotinib
Back to searchMolecule Structure
Scientific Name
Tepotinib
Description of the Drug
Tepotinib is an oral tyrosine kinase inhibitor targeted against MET for the treatment of metastatic non-small cell lung cancer in patients exhibiting MET exon 14 skipping mutations.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB15133
http://www.drugbank.ca/drugs/DB15133
Brand Name(s)
Not Available
Company Owner(s)
Emd Serono Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Hepatocyte growth factor receptor | SINGLE PROTEIN | INHIBITOR | CHEMBL3717 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL1296895 |
Human Metabolome Database | HMDB0304846 |
DrugBank | DB15133 |
PubChem: Thomson Pharma | 92728605 |
PubChem | 25171648 |
LINCS | LSM-45557 |
Nikkaji | J3.099.915K |
PDBe | 3E8 |
BindingDB | 50065457 |
EPA CompTox Dashboard | DTXSID70149132 |
DrugCentral | 5424 |
ChemicalBook | CB72550731 |
Guide to Pharmacology | 8293 |
ZINC | ZINC000043202335 |